



ASX Announcement

9 June 2020

Pharma Dynamics successfully launches Creso's Cannamics in South Africa

Highlights

- Pharma Dynamics launched Creso's developed cannaQIX®Regular, under the brand of **Cannamics** in South Africa in major retail chains
- Pharma Dynamics, a subsidiary of Lupin Limited (NSE:LUPIN), is a leading pharmaceutical company in South Africa and ranks as the fifth biggest generic player in the country
- Cannamics will be sold through independent and major pharmacy retailer chains across South Africa



Creso Pharma Limited (ASX:CPH) ('Creso Pharma' or 'the Company') is pleased to announce that its commercial partner Pharma Dynamics has successfully launched cannaQIX®Regular under the brand name **Cannamics** nationwide.





Pharma Dynamics - a subsidiary of Lupin Limited (NSE:LUPIN) - is a leading pharmaceutical company in South Africa, and is ranked the fifth biggest generic pharmaceutical company in SA. Pharma Dynamics leads with high quality generics at affordable prices and is well-known for its investments into innovative wellness programs towards holistic healthcare. Its growing over-the-counter range includes; cold and flu, allergy, heartburn and immune booster products. The organization also has a significant prescription portfolio with cardiovascular and central nervous system products consistently prescribed and recommended by leading doctors and pharmacists countrywide.

Cannamics. Simple as CBD should be.



Cannamics is glucose-free and contains no tetrahydrocannabinol (THC). The standardized, user-friendly strength and formulation allows precise dosage control and the pastilles have a more palatable taste compared to oils.

Cannamics has been developed to Good Manufacturing Practice standards and is produced in Switzerland by Creso Pharma’s partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality with a “Swiss Made” label.

Dr. Miri Halperin Wernli, Co-Founder and CEO said: “We are very excited that Pharma Dynamics managed such a great launch of cannaQIX®Regular, **Cannamics in South Africa**, providing a strong basis to enter further countries in Africa.



Tommy Scott, Business Development head from Pharama Dynamics said: “In spite of COVID-19 lockdown we managed to launch Cannamics, which brings recognized benefits in these difficult times. We are excited to enter this new category with such a renowned partner in the CBD space ”.

Ends

Authority and Contact Details

This announcement has been authorised for release by Dr. Miri Halperin Wernli CEO Creso Pharma

For further information, please contact:

Investor Enquiries

EverBlu Capital

E: info@everblucapital.com

P: +61 2 8249 0000

Released through:

Ben Jarvis, Six Degrees Investor Relations: Ph: +61 (0) 413 150 448

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

About Pharma Dynamics

Pharma Dynamics is the 10th largest pharmaceutical company in South Africa (SA) with a well-established footprint spanning across several African countries. As of 2012, it maintains its position as the biggest supplier of cardiovascular pharmaceuticals in SA, both in terms of value and volume. It boasts with a range of products across therapeutic areas including cardiovascular (CVS), central nervous system (CNS), gastrointestinal and men’s health therapies. In 2013, it entered the SA anti-infective market, supplying IV antibiotics to



hospitals. The firm's over-the-counter (OTC) product portfolio is also growing and includes antihistamines and allergy treatments, cold & flu medication and heartburn treatment, among others.

Pharma Dynamics is wholly owned by Lupin Laboratories, the fourth largest generic pharmaceutical company globally by market capitalisation.

About Domaco, Dr. med Aufdermaur AG

Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma development company that owns the rights to a number of innovative delivery systems used to administer active ingredients through galenic forms which is a way of preparing and compounding medicines in order to optimise their absorption.

To learn more please visit: www.domaco-pharma.com

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation. The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.